A Clinical Trial of NG-348 for the Treatment of Solid Tumors
Latest Information Update: 17 Jan 2023
At a glance
- Drugs NG-348 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 05 Jan 2023 According to an Akamis Bio media release, PsiOxus Therapeutics has changed its name to Akamis Bio.
- 16 Mar 2020 New trial record